The approved anti-inflammatory and cancer management drug, cepharanthine, has been found to inhibit endolysosomal trafficking of LDL and free cholesterol via binding and inhibiting NPC1, subsequently increasing the lysosomal pH [76]. This evidence concerns the gene NPC1 and cancer.